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Objective
The aim of our study was to assess the pollen sensitiza-
tion patterns by means of molecular diagnosis approach
in the region of Pilsen, Czech Republic.
Methods
The microarray system ImmunoCAP ISAC has been used
for specific IgE detection to 113 different allergenic mole-
cules. Sera from 789 patients sensitized to at least one
pollen-derived molecule were subject of analysis. These
patients suffered from at least one of the following diag-
noses: chronic rhinitis (62%), bronchial asthma (33%),
atopic dermatitis (28%), urticaria or angioedema (28%)
and/or anaphylaxis (11%). Patient age ranged from 2 to
68 years, with a mean age of 32,4 years. The sex ratio was
37% men to 63% women.
Results
The most frequent sensitization rate was observed to
grass-derived species-specific molecules (82,2% overall),
the most frequent being Phl p 1 (66,3%), markedly over-
whelming sensitization rates to any non-pollen-derived
molecule. The second one were pollen-derived PR-10
molecules (53,2% overall), of which the large majority
included Bet v 1 (52,3%). Sensitization to these two types
of pollen components (and their co-sensitizations with
other components) forms the vast majority of pollen sensi-
tizations. The patterns of co-sensitization is presented by
means of Venn diagram approach. Sensitization to
Cupressaceae-derived molecules was observed in 16,0% of
subjects, to Oleaceae derived-molecules in 12,5% (Ole e 1
and Ole e 9 in 9,0% and 3,8% resp.) and to the plane tree-
derived molecules Pla a 2 and Pla a 3 in 15,4% and 4,1%
resp; these relatively high rates were surprising as the
respective pollens have not been considered as important
in the region. The sensitization rates for further molecules
were: Art v 1 - 13,4%, Pla l 1 - 11,4%, Che a 1 - 9,9%, Par j
2 - 0,9%, Sal k 1 - 0,6% and Amb a 1 - 0,3%. The sensitiza-
tion rates to cross-reacting molecules were generally not
as high as reported from other regions (profilins 16,2%,
polcalcins 5,5%, LTPs 6,7%). Only 1,8% patients reacted to
pollen-derived panallergen and not simultaneously to a
pollen species-specific component.
Conclusion
Molecular diagnosis of allergy gives a more precise and
comprehensive insight into pollen sensitization patterns
than extract-based testing, allowing for better understand-
ing of the sensitization process and regional differences.
The data presented may help to improve diagnostic and
treatment specific procedures in the respective region.
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